Physiomics AI Stock Analysis
Want to see GB:PYC full AI Analyst Report?
Physiomics (PYC) AI Stock Analysis
Physiomics
(LSE:PYC)
Low score driven mainly by weak financial performance from ongoing losses and cash consumption, along with bearish technical indicators; valuation offers little support.
Physiomics (PYC) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 1.43M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.04M
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 0.61
- Revenue Growth
- 20.05%
- EPS Growth
- -11.11%
- Country
- UK
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Physiomics Business Overview & Revenue Model
Company Description
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced...
Physiomics Financial Statement Overview
Summary
Weak income statement and cash flow reflect negative margins and persistent cash burn typical of R&D-stage biotech, partially offset by a clean balance sheet with minimal debt.
Income Statement
25NegativeBalance Sheet
72PositiveCash Flow
18Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 941.22K | 941.22K | 784.00K | 543.25K | 597.35K | 830.27K |
| Gross Profit | -801.20K | -797.20K | -435.08K | -677.43K | -581.62K | -429.01K |
| EBITDA | -792.31K | -788.31K | -448.21K | -659.80K | -561.57K | -347.84K |
| Net Income | -697.03K | -697.03K | -415.25K | -609.35K | -477.26K | -253.14K |
Balance Sheet | ||||||
| Total Assets | 788.55K | 788.55K | 892.03K | 422.60K | 674.39K | 1.12M |
| Cash, Cash Equivalents and Short-Term Investments | 418.63K | 418.63K | 461.24K | 191.07K | 416.59K | 687.67K |
| Total Debt | 0 | 0 | 0 | 3,825 | 7,354 | 0 |
| Total Liabilities | 264.57K | 264.57K | 199.85K | 140.08K | 142.67K | 140.61K |
| Stockholders Equity | 523.98K | 523.98K | 692.17K | 282.53K | 531.72K | 974.81K |
Cash Flow | ||||||
| Free Cash Flow | -566.17K | -566.17K | -550.08K | -565.44K | -271.50K | -358.62K |
| Operating Cash Flow | -561.74K | -561.74K | -546.14K | -548.13K | -264.86K | -349.25K |
| Investing Cash Flow | -4,426 | -4,426 | -3,413 | -15.21K | -6,219 | -9,370 |
| Financing Cash Flow | 523.56K | 523.56K | 819.73K | 337.83K | 0 | 2,845 |
Physiomics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PYC, the sentiment is Negative. The current price of 0.42 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.49, and below the 200-day MA of 0.50, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 22.27 is Positive, neither overbought nor oversold. The STOCH value of 67.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PYC.
Physiomics Peers Comparison
Overall Rating
GB:IXI55Neutral
GB:VAL46Neutral
GB:TCF42Neutral- GB:PYC41Neutral
GB:OBD40Underperform
GB:OPTI32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:IXI | 55Neutral | GBP 28.47M | -6.50 | -16.18% | ― | 13.04% | 15.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:VAL | 46Neutral | GBP 2.11M | -0.81 | -71.49% | ― | -34.36% | 57.45% |
| GB:TCF | 42Neutral | GBP 4.64M | -1.70 | -93.92% | ― | ― | 55.56% |
| GB:PYC | 41Neutral | GBP 1.99M | -2.13 | -152.03% | ― | 20.05% | -11.11% |
| GB:OBD | 40Underperform | GBP 16.13M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
| GB:OPTI | 32Underperform | GBP 4.70M | -1.10 | -77.85% | ― | 11.90% | -2864.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:PYC | Physiomics plc | 0.42 | 0.01 | 1.19% | |
| GB:TCF | Evgen Pharma | 0.17 | -0.04 | -19.05% | |
| GB:IXI | IXICO plc | 12.75 | 1.50 | 13.33% | |
| GB:OPTI | OptiBiotix Health | 4.55 | -3.70 | -44.85% | |
| GB:OBD | Oxford BioDynamics | 0.12 | -0.17 | -58.93% | |
| GB:VAL | ValiRx plc | 0.15 | -0.08 | -34.04% |
Physiomics Corporate Events
Physiomics Wins New MIDD Contract as Recent Awards Surpass Annual Revenue
PositivePhysiomics plc, a specialist in model-informed drug development and quantitative pharmacology, has secured a new £102,000 contract for MIDD work incorporating pharmacokinetic and pharmacodynamic modelling. The company, whose client base includes majo...
Physiomics Wins £119k Modelling Contract and Explores New Markets for Dosing Tech
PositivePhysiomics has secured a new £119,000 contract for model-informed drug development work that includes pharmacokinetic and pharmacodynamic modelling, underlining demand for its quantitative expertise in supporting therapeutic development. Management h...
Physiomics posts record income, expands biometrics amid higher one-off costs
NeutralPhysiomics reported record total income of £1.06 million for the year to 30 June 2026, up 26.5% and its best performance since inception, driven by strong Modelling & Simulation work and first-time revenue from its new Biometrics service line. Howeve...
Physiomics’ Contract Wins Highlight Commercial Shift and Growth Momentum
PositivePhysiomics has secured new contracts worth more than £205,000, bringing total awards over just four months to above £750,000 and nearing the company’s full-year 2024-2025 revenue. The wins span its complementary service lines and reflect strengthenin...
Investor Robert McFadden Builds 3.02% Stake in Physiomics
PositivePhysiomics plc, a UK-based provider of advanced modelling, data science and biostatistics services to the pharmaceutical and biotechnology industries, supports drug development and personalised medicine through cutting-edge computational tools and it...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026